MIRODENAFIL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H37N5O5S
Molecular Weight	531.667
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCOC1=CC=C(C=C1C2=NC3=C(N(CC)C=C3CCC)C(=O)N2)S(=O)(=O)N4CCN(CCO)CC4

InChI

InChIKey=MIJFNYMSCFYZNY-UHFFFAOYSA-N

InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27034723
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17640490

The inhibition of cyclic nucleotide Phosphodiesterase type 5 (PDE5) has been clinically validated as an effective treatment for erectile dysfunction. One of them is mirodenafil (formerly known as SK-3530) approved only in Korea. This drug was developed by SK Chemicals and marketed under the trade name Mvix.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 5A 30 Target ID: CHEMBL1827 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27034723	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Erectile dysfunction 35 Sources: https://www.skchemicals.com/page/ls/eng/product/info4_01.do	Primary	Approved 8429	Mvix Approved Use Treatment of erectile dysfunction(ED)
Urologic diseases 2 Sources: https://clinicaltrials.gov/ct2/show/NCT01232010	Primary	Phase I 428	Unknown Approved Use Unknown
Kidney disease 6 Sources: https://clinicaltrials.gov/ct2/show/NCT01232010	Primary	Phase I 428	Unknown Approved Use Unknown
Renal insufficiency 40 Sources: https://clinicaltrials.gov/ct2/show/NCT01232010	Primary	Phase I 428	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats.	2007	17318927
Validation of a HPLC method for the quantification and purity determination of SK3530 in drug substance and tablet.	2007 Feb 19	17134866
Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats.	2009 Sep	19639551
Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541.	2010	20456834

Sample Use Guides

In Vivo Use Guide

One tablet (Mirodenafil 50mg or 100mg) recommended dosing frequency is once per day. Taken orally approximately 60 minutes before sexual activity. Sexual stimulation is required for a response to treatment.

Route of Administration: Oral

In Vitro Use Guide

The in vitro incubation of [14C]SK-3530 (MIRODENAFIL )with rat and human plasma samples resulted in high protein binding rates of more than 97%; binding was concentration-independent over the range tested (1–100 µmol/L), with no difference between the species show.

Name

Type

Language

MIRODENAFIL

Official Name

English

Mirodenafil [WHO-DD]

Common Name

English

SK-3530 FREE BASE

Code

English

MIRODENAFIL [INCI]

Common Name

English

5-ETHYL-2-(5-((4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)SULFONYL)-2-PROPOXYPHENYL)-7-PROPYL-3,5-DIHYDRO-4H-PYRROLO(3,2-D)PYRIMIDIN-4-ONE

Systematic Name

English

SK3530 FREE BASE

Code

English

mirodenafil [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2127